Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevention and Treatment of Stretch Marks With Stratamark™

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03377231
Recruitment Status : Completed
First Posted : December 19, 2017
Last Update Posted : December 20, 2017
Sponsor:
Information provided by (Responsible Party):
Stratpharma AG

Brief Summary:

Stretch marks (striae distensae) are a form of scarring that is a natural result of pregnancy, obesity and in some instances occur due to puberty or steroid use. For some people, the stretch marks do not cause a problem, but in many circumstances they can cause physical symptoms such as itchiness, tenderness and pain. For many people stretch marks are also embarrassing and can have detrimental effects on a patient's mood and self-esteem. Stretch marks that result from pregnancy most commonly occur on the abdomen, breasts and thighs.

Topical silicone gel was developed nearly thirty years ago to be used in the treatment of widespread hypertrophic scars (abnormal scars, which may be red or raised/depressed itchy or painful). Since this time it has been used successfully on most scar types. . Since stretch marks are a form of scarring it is thought that topical silicone gel may be helpful for this scar type also. Stratamark™ has been developed using different forms of silicone polymers, in a gel format, that dries to form a very thin and flexible silicone gel sheet making it a convenient therapy for the treatment and prevention of stretch marks.

The aim of this clinical research study is to prove or disprove the efficacy, safety and tolerability of Stratamark™ in the prevention and treatment of stretch marks. In addition, the knowledge gained from this study may be of benefit to many future patients


Condition or disease Intervention/treatment Phase
Stretch Mark Device: Stratamark® Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 272 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: The study involved the use of Stratamark® in prevention and treatment of stretch marks in 2 study arms.
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Assessment of Efficacy, Safety and Tolerability of Stratamark® (Innovative Self-drying Silicone Gel) in the Treatment and Prevention of Striae Distensae
Actual Study Start Date : July 11, 2013
Actual Primary Completion Date : May 16, 2016
Actual Study Completion Date : May 16, 2016

Arm Intervention/treatment
Experimental: Prevention Device: Stratamark®
Film-forming dressing for the prevention and treatment of stretch marks.

Experimental: Treatment Device: Stratamark®
Film-forming dressing for the prevention and treatment of stretch marks.




Primary Outcome Measures :
  1. Product efficacy in prevention of stretch marks [ Time Frame: 5 months ]

    Investigator-assessed prevalence of stretch marks in the patients treated with Stratamark vs. a literature-based control group.

    Measurement tool: dichotomous scale for the occurrence of stretch marks (0 no stretch marks - 1 appearance of stretch marks).


  2. Product efficacy in treatment of stretch marks [ Time Frame: 6 months ]

    Investigator-assessed improvement in stretch marks severity of patients treated with Stratamark from baseline to last assessment.

    Measurement tool: likert scale for stretch marks severity (0 to 6 - 0 being no stretch marks and 6 being severe).



Secondary Outcome Measures :
  1. Severity of stretch marks developed in prevention [ Time Frame: 5 months ]

    Investigator-assessed severity of stretch marks developed in prevention patients.

    Measurement tool: likert scale for stretch marks severity (0 to 6 - 0 being no stretch marks and 6 being severe).


  2. Patient product evaluation in prevention of stretch marks [ Time Frame: 5 months ]

    Patient-perceived product efficacy, tolerability, ease of use and feel on skin at trial completion.

    Measurement tool: likert scale for product evaluation (0 to 4 - 0 being unsatisfactory and 4 being excellent).


  3. Product efficacy in treatment of stretch marks [ Time Frame: 6 months ]

    Investigator-assessed improvement in stretch marks color of patients treated with Stratamark from baseline to last assessment.

    Measurement tool: likert scale for stretch marks color assessment (-4 to +4 - -4 being stark white compared to surrounding skin and +4 being purple).

    0 being normal skin color, is considered to be the optimal value.


  4. Product efficacy in treatment of stretch marks [ Time Frame: 6 months ]

    Investigator-assessed improvement in stretch marks pruritus of patients treated with Stratamark from baseline to last assessment.

    Measurement tool: likert scale for stretch marks pruritus assessment (0-10 - 0 being no pruritus and 10 being worst possible pruritus).


  5. Patient product evaluation in treatment of stretch marks [ Time Frame: 6 months ]

    Patient-perceived product efficacy, tolerability, ease of use and feeling on skin at trial completion.

    Measurement tool: likert scale for product evaluation (0 to 4 - 0 being unsatisfactory and 4 being excellent).


  6. Patient evaluation of stretch marks in treatment [ Time Frame: 6 months ]

    Patient-perceived change in color and noticeability of stretch marks at trial completion.

    Measurement tool: likert scale for stretch marks patient evaluation (-4 to +4 - -4 being much worse and +4 being cleared).




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Pregnant women
Accepts Healthy Volunteers:   Yes
Criteria

Prevention arm - Inclusion Criteria:

  • Healthy pregnant woman (nulliparous or multiparous) entering into their third trimester (26-28 weeks, visit 1)
  • Not having striae on their abdomen at the time of trial enrollment

Prevention arm - Exclusion Criteria:

  • Any significant medical or surgical conditions
  • Current medications liable to interfere with study results or change the skin's response to therapy

Treatment arm - Inclusion Critera:

• Confirmed SD on their abdomen post-delivery

Treatment arm - Exclusion Criteria:

  • Any significant medical or surgical conditions
  • Current medications liable to interfere with study results or change the skin's response to therapy

Layout table for additonal information
Responsible Party: Stratpharma AG
ClinicalTrials.gov Identifier: NCT03377231    
Other Study ID Numbers: SPASK01AU001
SSA/13/WCHN/42 ( Other Identifier: WCHN Human Research Ethics Committee )
First Posted: December 19, 2017    Key Record Dates
Last Update Posted: December 20, 2017
Last Verified: December 2017
Keywords provided by Stratpharma AG:
Pregnancy, Striae gravidarum, Striae distensae, Women's health
Additional relevant MeSH terms:
Layout table for MeSH terms
Striae Distensae
Skin Manifestations
Signs and Symptoms